Bre–Ved–ZA satisfies these requisites; indeed, this anti-CD30 antibody enables the ADC to target ZA to the CD30+ tumor cells, leading to the stimulation of Vδ2 T-lymphocytes. Here, TNFRSF8 is linked to neoplasm.